of Human Pharmacology and Drug Therapy. 2019;39(11): 1077-1094.
5. Falagas ME, Vouloumanou EK, Samonis G, et al. Fosfomycin. Clin Microbiol Rev. 2016;29(2):321-347.
6. Tran MT. New ways of using old antibiotics in pediatrics: Focus on fosfomycin. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2023;43(7):705-712.
7. Pfausler B, Spiss H, Dittrich P, et al. Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomy-associated ventriculitis. Journal of Antimicrobial Chemotherapy. 2004;53(5):848-852.
8. König C, Martens-Lobenhoffer J, Czorlich P, et al. Cerebrospinal fluid penetration of fosfomycin in patients with ventriculitis: an observational study. Ann Clin Microbiol Antimicrob. 2023;22:29.
9. Lenzi A, Saccani B, Di Gregorio M, et al. Fosfomycin-Containing Regimens for the Treatment of Central Nervous System Infections in a Neonatal Intensive Care Unit: A Case Series Study. Antibiotics (Basel). 2024;13(7):667.
10. Tsegka KG, Voulgaris GL, Kyriakidou M, et al. Intravenous fosfomycin for the treatment of patients with central nervous system infections: evaluation of the published evidence. Expert Rev Anti Infect Ther. 2020;18(7):657-668.
11. Roussos N, Karageorgopoulos DE, Samonis G, et al. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. International Journal of Antimicrobial Agents. 2009;34(6):506-515.
12. Candel FJ, David MM, López JB. New perspectives for reassessing fosfomycin: applicability in current clinical practice. Rev Esp Quimioter. 2019;32(Suppl 1):1-7.
13. Antonello RM, Di Bella S, Maraolo AE, et al. Fosfomycin in continuous or prolonged infusion for systemic bacterial infections: a systematic review of its dosing regimen proposal from in vitro, in vivo and clinical studies. Eur J Clin Microbiol Infect Dis. 2021;40(6):1117-1126.
14. Busse D, Simon P, Petroff D, et al. High-Dosage Fosfomycin Results in Adequate Plasma and Target-Site Exposure in Morbidly Obese and Nonobese Nonhyperfiltration Patients. Antimicrob Agents Chemother. 2022;66(6):e02302-21.
15. Rodríguez-Gascón A, Canut-Blasco A. Deciphering pharmacokinetics and pharmacodynamics of fosfomycin. Rev Esp Quimioter. 2019;32(Suppl 1):19-24.
16. Asuphon O, Montakantikul P, Houngsaitong J, et al. Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic/pharmacodynamic (PK/PD) simulation. International Journal of Infectious Diseases. 2016;50:23-29.
17. Traunmüller F, Popovic M, Konz KH, et al. A Reappraisal of Current Dosing Strategies for Intravenous Fosfomycin in Children and Neonates. Clin Pharmacokinet. 2011;50(8):493-503.
18. CLSI. MIC Breakpoint Table [Internet]. cit. 15-12-2024. Available from: https://clsi.org/media/wxwfzvpd/part_b_clsi_vs_fda-breakpoints.xlsx.
19. EUCAST. EUCAST guidance on use of fosfomycin i.v. breakpoints [on-line]. cit. 15-12-2024. Available from: https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Guidance_documents/Use_of_fosfomycin_iv_breakpoints_General_advice_20240528.pdf.
20. WHO. The WHO AWaRe (Access, Watch, Reserve) antibiotic book [Internet]. cit. 29-082024. Available from: https://www.who.int/publications/i/item/9789240062382.
21. SÚKL. Fomicyt [on-line]. cit. 29-08-2024. Available from: https://prehledy.sukl.cz/prehledy/v1/dokumenty/11675.
22. van de Beek D, Cabellos C, Dzupova O, et al. ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. Clin Microbiol Infect. 2016;22 Suppl 3:S37-62.
23. Pipitone G, Di Bella S, Maraolo AE, et al. Intravenous Fosfomycin for Systemic Multidrug-Resistant Pseudomonas aeruginosa Infections. Antibiotics (Basel). 2023;12(12):1653.
24. Tsegka KG, Voulgaris GL, Kyriakidou M, et al. Intravenous fosfomycin for the treatment of patients with bone and joint infections: a review. Expert Rev Anti Infect Ther. 2022;20(1):33-43.
25. SÚKL. Urifos [Internet]. cit. 29_08-2024. Available from: https://prehledy.sukl.cz/prehledy/v1/dokumenty/13159.
26. Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. Int J Infect Dis. 2011;15(11):e732-739.
27. Merative Micromedex® [Internet]. cit. 20-07-2023. Micromedex® Drug Interactions Results. Available from: http://micromedex.fnusa.cz/micromedex2/librarian/PFDefault/evidenceexpert.ShowDrugInteractionsResults.
28. Kollu K, Bas A, Gok F, et al. Effect of fosfomycin-induced hypernatremia on patients' hospital stay length and survival. Ir J Med Sci. 2024;193(5):2453-2459. doi: 10.1007/s11845-024-03718.
29. Florent A, Chichmanian RM, Cua E, et al. Adverse events associated with intravenous fosfomycin. International Journal of Antimicrobial Agents. 2011;37(1):82-83.
30. Al Jalali V, Matzneller P, Wulkersdorfer B, et al. Clinical Pharmacokinetics of Fosfomycin after Continuous Infusion Compared with Intermittent Infusion: a Randomized Crossover Study in Healthy Volunteers. Antimicrob Agents Chemother. 2020;65(1):e01375-20.
31. Ashley C, Dunleavy A. The Renal Drug Handbook [Internet]. 5th ed. CRC Press; 2019 [citován 3. leden 2023]. Available from: https://www.medicinainterna.net.pe/sites/default/files/The_Renal_Drug_Handbook_The_Ultimate.pdf.
32. Mensa J, Barberán J, Soriano A, et al. Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa: Guidelines by the Spanish Society of Chemotherapy. Rev Esp Quimioter. 2018;31(1):78-100.
33. Gatti M, Pea F. Antimicrobial Dose Reduction in Continuous Renal Replacement Therapy: Myth or Real Need? A Practical Approach for Guiding Dose Optimization of Novel Antibiotics. Clin Pharmacokinet. 2021;60(10):1271-1289.
34. Parker S, Lipman J, Koulenti D, et al. What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review. International Journal of Antimicrobial Agents. 2013;42(4):289-293.
35. Baltogianni M, Dermitzaki N, Kosmeri C, et al. Reintroduction of Legacy Antibiotics in Neonatal Sepsis: The Special Role of Fosfomycin and Colistin. Antibiotics (Basel). 2024;13(4):333.
36. Taylor CG, Mascarós E, Román J, et al. Enteropathogenic E. coli gastroenterocolitis in neonates treated with fosfomycin. Chemotherapy. 1977;23 Suppl 1:310-314.
37. Keating GM. Fosfomycin Trometamol: A Review of Its Use as a Single-Dose Oral Treatment for Patients with Acute Lower Urinary Tract Infections and Pregnant Women with Asymptomatic Bacteriuria. Drugs. 2013;73(17):1951-1966.
38. Lebedevs T. Fosfomycin and breastfeeding. Aust Prescr. 2020;43(4):113.
39. Bouchet JL, Quentin C, Albin H, et al. Pharmacokinetics of fosfomycin in hemodialyzed patients. Clin Nephrol. 1985;23(5):218-221.
40. Dalet F, Bade G, Roda M. Pharmacokinetics of fosfomycin during hemodialysis. Chemotherapy. 1977;23 Suppl 1:2106.
41. Schmidt JJ, Bode-Böger SM, Wilhelmi M, et al. Pharmacokinetics and total removal of fosfomycin in two patients undergoing intermittent haemodialysis and extended dialysis: prescription needs to avoid under-dosing. Journal of Antimicrobial Chemotherapy. 2016;71(9):2673-2674.
42. Gerecke LKV, Schmidt JJ, Hafer C, et al. Fosfomycin single- and multiple-dose pharmacokinetics in patients undergoing prolonged intermittent renal replacement therapy. Journal of Antimicrobial Chemotherapy. 2022;77(1):169-173.
43. Gattringer R, Meyer B, Heinz G, et al. Single-dose pharmacokinetics of fosfomycin during continuous venovenous haemofiltration. J Antimicrob Chemother. 2006;58(2):367-371.